LINC01996: A Potential Drug Target and Biomarker (G400568)

Target Name: LINC01996

NCBI ID: G400568

LINC01996

Other Name(s): Long intergenic non-protein coding RNA 1996 | long intergenic non-protein coding RNA 1996

LINC01996: A Potential Drug Target and Biomarker

Non-protein-coding RNAs (ncRNAs) have emerged as a promising area of 鈥嬧?媟esearch in recent years, as they have been shown to play critical roles in various cellular processes. One class of ncRNAs, known as long intergenic non-protein coding RNAs ( LINCs), have garnered particular attention due to their ability to transcribe from non-coding regions of the genome and their involvement in various biological processes. In this article, we will explore the potential drug target and biomarker properties of LINC01996.

LINC01996 is a non-coding RNA molecule that was identified using RNA sequencing (RNA-seq) data from the human brain. It has a unique 21-nt length and is located between the genes encoding transcription factor binding sites (TFBS) and the genes encoding the protein involved in the detoxification of xenobiotics, such as aryl hydrocarbon receptor (AhR) and opiate receptor (OPR). LINC01996 is expressed in all cell types and has been shown to be highly expressed in the brain, suggesting a potential role in brain function.

Despite its potential involvement in brain function, LINC01996 has not yet been fully characterized. However, studies have shown that LINC01996 is involved in various cellular processes, including cell growth, differentiation, and stress response. LINC01996 has also been shown to play a role in the regulation of gene expression, as it can physically interact with known RNA binding proteins and can also act as a scaffold to recruit RNA binding proteins to specific genomic locations.

One of the most promising aspects of LINC01996 is its potential as a drug target. The fact that LINC01996 is involved in various cellular processes and has been shown to play a role in gene regulation suggests that it may be a valuable target for small molecules or other therapeutic agents. Additionally, LINC01996's unique expression pattern in the brain suggests that it may be a particularly good candidate for drugs that are targeted to the brain.

In addition to its potential as a drug target, LINC01996 may also have potential as a biomarker. The fact that LINC01996 is expressed in all cell types and is highly expressed in the brain suggests that it may be a useful biomarker for various neurological and psychiatric disorders . Additionally, since LINC01996 is involved in the regulation of gene expression, it may be a useful biomarker for diseases that are characterized by disruptions in gene expression.

In conclusion, LINC01996 is a promising candidate for drug targeting and biomarker. Its unique expression pattern and involvement in various cellular processes make it an attractive target for small molecules and other therapeutic agents. Additionally, its potential as a biomarker for neurological and psychiatric disorders makes it a valuable tool for the diagnosis and treatment of these disorders. Further research is needed to fully explore the potential of LINC01996 as a drug target and biomarker.

Protein Name: Long Intergenic Non-protein Coding RNA 1996

The "LINC01996 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC01996 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets